series-a
Stage
1
Investors
About
SynCardia Systems develops and manufactures the SynCardia Total Artificial Heart, an FDA-approved medical device that replaces both failing ventricles in patients with end-stage biventricular heart failure as a bridge to heart transplantation.
Explore SynCardia Systems's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.